Related Articles
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission
Molecular MRD after induction chemotherapy identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.Patients achieving M
FDA Approves Breyanzi for Relapsed, Refractory Follicular Lymphoma
The Food and Drug Administration approved Breyanzi for patients with pretreated, relapsed or refractory follicular lymphoma.
Targeting the postsynaptic scaffolding protein PSD-95 enhances BDNF signaling to mitigate depression-like behaviors in mice
Structurally supporting TrkB signaling enhances the antidepressant effects of BDNF in mice.
Back morphology and walking patterns mean 13.8 years after… : PAIN Reports
gery compared with controls. It is unclear if walking patterns segregate surgically treated LDH adolescents and controls at mean 13-year follow-up. Objectives: Here, we analyzed…
True or False: Basal Cell Carcinoma on Vermilion Lip
Is basal cell carcinoma on the vermilion lip a distinctly rare phenomenon, sparsely documented in existing literature?
Whole-genome methylation profiling reveals regions… : PAIN
ethylation, an epigenetic phenomenon, we measured genome-wide DNA methylation using the Illumina MethylationEPIC platform with blood samples from participants in the Orofacial Pain: Prospective Evaluation…
Q&A with Dr. Dorafshar, Dr. Lopez, and Dr. Reid, authors of Computer-Assisted Planning in Craniofacial Surgery, 1st Edition – The Bookmark
AD: During my training at Johns Hopkins, I observed the “art” of craniofacial surgery, where experienced practitioners seamlessly envisioned and executed procedures. Upon starting my…
CD123-Targeting Therapy Advances BPDCN Treatment Landscape | Blood Cancers Today
Tagraxofusp is the first drug for BPDCN, and the first CD123-targeting drug in oncology, to receive FDA approval.
Jefferson Health, Lehigh Valley Health Network sign definitive agreement for $14B merger
Philadelphia-based Jefferson Health and Allentown, Pennsylvania-based Lehigh Valley Health Network (LVHN) are one step closer to consummating a $14 billion merger announced late last year.
Managing and Treating Type 2 Diabetes
Type 2 diabetes affects 90-95% of the 38 million Americans suffering from the disease. Learn how to best treat this disease while earning CME credits…